Enivta" s Immunotherapy, Aait, Involves 4 Major Cell Types Including:
AAIT is an acronym for autologous adoptive immune therapy and describes a therapy derived from the patients own blood, and is re-infused during treatment. There are myriad strategies for immunotherapy and just as many Stage 4 breast cancer treatments that fall under the heading autologous adoptive immunotherapy. That being said not all options are comparable.
Enivta's immunotherapy, AAIT, involves 4 major cell types including:
=> Natural killer cells
=> Natural killer T cells
=> Cytokine-induced killer cells
=> Cytotoxic T lymphocytes
The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the primary focus of Envitas AAIT immunotherapy serums.
Keys to Envita's AAIT Uniqueness
1) Envita's protocol for AAIT is designed to optimize the expansion of natural killer cells - the most potent cancer fighting component of the cellular immune system. Most immune therapies do include natural killer cells, and those that do only expand them in low numbers with little activation.
2) Envita's AAIT protocol takes only 4-5 weeks to grow your cells, so you can begin to experience benefits quickly. Moreover, while other immune therapies administer just 100-200 million cells per treatment, Envita delivers roughly 100 times as many during the course of your treatment.
3) Multitudes of published studies demonstrate the effects of adoptive immune therapy in patients for which Envita has identified and improved upon the best. Company protocol insists upon the highest-level of procedure for the expansion and application of cells for each immunotherapy treatment.
4) Unlike other published immune therapies, Envita's AAIT is the only one that can be used as a stand-alone. Moreover, it may also be administered in conjunction with other therapies to enhance the cells effects in patients an incomparable benefit. Envita's AAIT therapy is not focused solely on expanding cells in the lab; rather, our goal also includes keeping them active until reintroduced to the patients body.
5) Envitas AAIT offers far greater tumor kill, or cytotoxicity than that of other well-regarded cancer cell vaccines / immunotherapies found throughout the world. In brief, this means Envitas activated natural killer cells in AAIT deliver considerably higher tumor obliteration.
6) In summary, the most direct manner to stack Envitas proprietary immunotherapy against the others, includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envitas AAIT immunotherapy consistently delivers significantly greater tumor kill.
b. Quantity (how many cells you get back) Stage 4 colon cancer Envitas AAIT immunotherapy comes with 100 times the cell dosage than the others.
c. Sterility (quality control measures) Envita AAIT immunotherapy is completely contaminant free.
If you have any questions concerning Envita's AAIT immunotherapy, please consult with Envita's team of physicians and patient educators. This immunotherapy is offered at Envitas international cancer center in Mexico.
Enivta's immunotherapy, AAIT, involves 4 major cell types including:
=> Natural killer cells
=> Natural killer T cells
=> Cytokine-induced killer cells
=> Cytotoxic T lymphocytes
The inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the primary focus of Envitas AAIT immunotherapy serums.
Keys to Envita's AAIT Uniqueness
1) Envita's protocol for AAIT is designed to optimize the expansion of natural killer cells - the most potent cancer fighting component of the cellular immune system. Most immune therapies do include natural killer cells, and those that do only expand them in low numbers with little activation.
2) Envita's AAIT protocol takes only 4-5 weeks to grow your cells, so you can begin to experience benefits quickly. Moreover, while other immune therapies administer just 100-200 million cells per treatment, Envita delivers roughly 100 times as many during the course of your treatment.
3) Multitudes of published studies demonstrate the effects of adoptive immune therapy in patients for which Envita has identified and improved upon the best. Company protocol insists upon the highest-level of procedure for the expansion and application of cells for each immunotherapy treatment.
4) Unlike other published immune therapies, Envita's AAIT is the only one that can be used as a stand-alone. Moreover, it may also be administered in conjunction with other therapies to enhance the cells effects in patients an incomparable benefit. Envita's AAIT therapy is not focused solely on expanding cells in the lab; rather, our goal also includes keeping them active until reintroduced to the patients body.
5) Envitas AAIT offers far greater tumor kill, or cytotoxicity than that of other well-regarded cancer cell vaccines / immunotherapies found throughout the world. In brief, this means Envitas activated natural killer cells in AAIT deliver considerably higher tumor obliteration.
6) In summary, the most direct manner to stack Envitas proprietary immunotherapy against the others, includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envitas AAIT immunotherapy consistently delivers significantly greater tumor kill.
b. Quantity (how many cells you get back) Stage 4 colon cancer Envitas AAIT immunotherapy comes with 100 times the cell dosage than the others.
c. Sterility (quality control measures) Envita AAIT immunotherapy is completely contaminant free.
If you have any questions concerning Envita's AAIT immunotherapy, please consult with Envita's team of physicians and patient educators. This immunotherapy is offered at Envitas international cancer center in Mexico.